MyMD Pharmaceuticals is a clinical stage pharmaceutical company focused on extending healthy lifespan. Developing drug products that target aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety and sleep disorders.

Currently, the company is working on two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a novel therapeutic shown to positively impact multiple conditions related to immunometabolic dysregulation. Supera-CBD is a synthetic cannabidiol that offers better bioavailability and potency than botanicals.